|
May 20
|
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
|
|
May 16
|
ARWR: Summer Webinar Series to Highlight Development Pipeline…
|
|
May 14
|
Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025
|
|
May 10
|
Arrowhead Pharmaceuticals Reports Substantial Fiscal Q2 Loss, Diverging from Analyst Expectations
|
|
May 10
|
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2024 Earnings Call Transcript
|
|
May 9
|
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
|
|
May 2
|
Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
|
|
Apr 29
|
Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
|
|
Apr 26
|
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
|
|
Apr 24
|
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
|
|
Apr 24
|
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
|
|
Apr 16
|
Turnstone Biologics Appoints William Waddill to its Board of Directors
|
|
Apr 16
|
Institutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest 6.6% drop adds to a year losses
|
|
Apr 7
|
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
|
|
Apr 4
|
Insider Sell: Chief Discovery/Trans Medicine James Hamilton Sells 6,000 Shares of Arrowhead ...
|
|
Mar 25
|
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
|
|
Mar 11
|
The 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024
|
|
Mar 9
|
Arrowhead Pharmaceuticals Inc CFO Kenneth Myszkowski Sells 40,000 Shares
|
|
Mar 8
|
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
|
|
Mar 6
|
Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Expensive For A Reason? A Look At Its Intrinsic Value
|